Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.

Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB.

Oncology. 2011;81(5-6):298-305. doi: 10.1159/000334456. Epub 2011 Dec 8.

PMID:
22156381
2.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators., Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

3.

The usefulness of dual energy X-ray and laser absorptiometry of the calcaneus versus dual energy X-ray absorptiometry of hip and spine in diagnosing manifest osteoporosis.

de Klerk G, van der Velde D, van der Palen J, van Bergeijk L, Hegeman JH.

Arch Orthop Trauma Surg. 2009 Feb;129(2):251-7. doi: 10.1007/s00402-008-0755-y. Epub 2008 Sep 30.

PMID:
18825395
4.

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S.

J Clin Oncol. 2008 Oct 20;26(30):4875-82. doi: 10.1200/JCO.2008.16.3832. Epub 2008 Aug 25.

PMID:
18725648
5.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG)..

Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.

PMID:
18718815
6.

Error occurred: cannot get document summary

PMID:
18427590

7.

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.

Cancer. 2008 Mar 1;112(5):1001-10. doi: 10.1002/cncr.23259.

8.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial..

N Engl J Med. 2007 May 3;356(18):1809-22.

9.

Burden of osteoporosis and fractures.

Keen RW.

Curr Osteoporos Rep. 2003 Sep;1(2):66-70. Review.

PMID:
16036067
10.

NSABP breast cancer clinical trials: recent results and future directions.

Mamounas EP.

Clin Med Res. 2003 Oct;1(4):309-26. Review.

11.

Global cancer statistics, 2002.

Parkin DM, Bray F, Ferlay J, Pisani P.

CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.

12.

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L.

J Clin Oncol. 2002 Aug 1;20(15):3219-24.

PMID:
12149294
13.

Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G.

N Engl J Med. 1998 Aug 6;339(6):357-63.

14.

Annual hazard rates of recurrence for breast cancer after primary therapy.

Saphner T, Tormey DC, Gray R.

J Clin Oncol. 1996 Oct;14(10):2738-46.

PMID:
8874335
15.

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.

Green JR, Müller K, Jaeggi KA.

J Bone Miner Res. 1994 May;9(5):745-51.

PMID:
8053405

Supplemental Content

Support Center